Markets open

LLY Eli Lilly

Healthcare · Close of 19 Nov 26

$1,351 -2.29%

⭐ Log in to follow stocks and set price alerts (free) Log in

19 Nov 2025SMA5019 Nov 2026
1 month+6.32%
3 months+7.62%
Year to date+25.72%
1 year+31.17%
52-week range$850.51 – $1,475
SMA50 / SMA200$1,262 / $1,116
RSI 1450
Avg daily move (ATR)3.3%
TrendUptrend

Financials (from SEC filings)

📅 Next earnings: 3 Feb 2027 · date estimated from last year

Revenue (TTM)$86.5B
Net income (TTM)$27.6B
EPS (TTM)$30.81
P/E (price ÷ EPS)43.9
Market cap$1.3T
Net margin31.9%

What changed in the latest quarter (Q3 2026)

Eli Lilly (LLY) – Q3 2026 (ended Sep 30, 2026)

  • Revenue: $24.4B, up 38.6% from the same quarter a year earlier.
  • Gross margin: 83.9%, slightly higher than 82.9% a year ago (operating margin was not provided).
  • Net margin: 26.4%, lower than 31.7% a year ago, so profit grew more slowly than sales.
  • Net income: $6.5B, up 15.5%. EPS was $7.22, up 16.3%.
  • Balance sheet: cash of $4.9B versus long-term debt of $47.0B.

This is a reported quarter from the 10-Q, not a derived one. Over the last 12 months, revenue was $86.5B and net income was $27.6B.

QuarterRevenueNet incomeEPSNet margin
Q3 2026ended 30 Sept 2026 $24.4B+38.6% YoY $6.5B+15.5% YoY $7.22+16.3% YoY 26.4%
Q2 2026ended 30 Jun 2026 $23.0B+47.7% YoY $7.1B+25.3% YoY $7.94+26.2% YoY 30.9%
Q1 2026ended 31 Mar 2026 $19.8B+55.5% YoY $7.4B+168.1% YoY $8.26+169.9% YoY 37.4%
Q4 2025*ended 31 Dec 2025 $19.3B+42.5% YoY $6.6B+50.5% YoY $7.39+51.4% YoY 34.4%
Q3 2025ended 30 Sept 2025 $17.6B+53.9% YoY $5.6B+475.4% YoY $6.21+480.4% YoY 31.7%
Q2 2025ended 30 Jun 2025 $15.6B+37.6% YoY $5.7B+90.8% YoY $6.29+91.8% YoY 36.4%

YoY = vs the same quarter a year earlier · quarters follow the company's fiscal year * Q4 = full year minus the first three quarters (EPS approximate)

Balance sheet as of 2026-09-30: Cash $4.9B · Long-term debt $47.0B · Equity $40.3B

Numbers from SEC EDGAR (the company's 10-Q/10-K filings), updated daily · AI summary from the numbers only, not investment advice ·Open the 10-Q filed 2026-10-29

🏛 US Congress trades in this stock (12 months)

Reports can arrive up to 45 days after the trade and give amount ranges only. By the time you see this, the trade is old news: no inside information, not a trading signal.

FiledMemberAsset Type Amount (range) Traded
12 Nov 26PDFDavid J. TaylorOH02 · selfLLYEli Lilly and Company Common Stock (LLY) Sell $1,001 - $15,000 3 Nov 269 days later
12 Nov 26PDFDavid J. TaylorOH02 · selfLLYEli Lilly and Company Common Stock (LLY) Sell $1,001 - $15,000 3 Nov 269 days later

See all trades

Today's AI analysis

The AI is analysing this stock. Refresh in a moment.

For education only, not a recommendation to buy or sell. Investing involves risk.